Adverse Interactions of Rofecoxib with Lisinopril in Spontaneously Hypertensive Rats

Dubey, Kiran; Balani, D K; Tripathi, Chandra Bhushan; Singh, Rajvir; Bajaj, Rajiv; Pillai, K. K.

doi:10.1081/clt-200066053

Cited by 5 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another COX-2 inhibitor, rofecoxib, caused an increase in blood pressure dependent on PGI 2 synthesis in normotensive Wistar-Kyoto rats (WKYs) and young spontaneously hypertensive rats (SHRs) fed a normal-salt or high-salt diet (Hocherl et al 2002 ). Rofecoxib also completely prevented the hypotensive effects of the ACEi inhibitor lisinopril in SHRs (Ricciotti et al 2018 ; Dubey et al 2005 ). Most importantly, clinical studies suggest that hypertension was more common in patients taking COX-2 inhibitors such as celecoxib and etoricoxib, and COX inhibition may attenuate the effects of some antihypertensive therapeutics (Mitchell et al 2020 ; Chan et al 2009 ).…”

Section: The Protective Role and Mechanism Of Cox-2 In Cardiovascular Diseasementioning

confidence: 99%

New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

Chen

Zhong

Feng

et al. 2021

Mol Med

View full text Add to dashboard Cite

Age-related cardiovascular disease is the leading cause of death in elderly populations. Coxibs, including celecoxib, valdecoxib, etoricoxib, parecoxib, lumiracoxib, and rofecoxib, are selective cyclooxygenase-2 (COX-2) inhibitors used to treat osteoarthritis and rheumatoid arthritis. However, many coxibs have been discontinued due to adverse cardiovascular events. COX-2 contains cyclooxygenase (COX) and peroxidase (POX) sites. COX-2 inhibitors block COX activity without affecting POX activity. Recently, quercetin-like flavonoid compounds with OH groups in their B-rings have been found to serve as activators of COX-2 by binding the POX site. Galangin-like flavonol compounds serve as inhibitors of COX-2. Interestingly, nabumetone, flurbiprofen axetil, piketoprofen-amide, and nepafenac are ester prodrugs that inhibit COX-2. The combination of galangin-like flavonol compounds with these prodrug metabolites may lead to the development of novel COX-2 inhibitors. This review focuses on the most compelling evidence regarding the role and mechanism of COX-2 in cardiovascular diseases and demonstrates that quercetin-like compounds exert potential cardioprotective effects by serving as cofactors of COX-2.

show abstract

Section: The Protective Role and Mechanism Of Cox-2 In Cardiovascular Diseasementioning

confidence: 99%

New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

Chen

Zhong

Feng

et al. 2021

Mol Med

View full text Add to dashboard Cite

show abstract

“…9 Captopril and zofenopril with their sulfhydrylic group maintain a cardiovascular (CV) protective effect even in the presence of cyclooxygenase inhibitors differentially to enalapril, 9 ramipril, 10 or lisinopril. 11 Sulfhydryl ACE inhibitors might have a cardioprotective mechanism of action, which only in part includes a prostaglandin-mediated mechanism. In the Valsartan in Acute Myocardial Infarction (VALIANT) study in which 92% patients were treated with aspirin or other antiplatelet agents, captopril had similar outcomes than valsartan or placebo.…”

Section: Introductionmentioning

confidence: 99%

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study

Borghi

Omboni

Novo

et al. 2017

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Abstract:The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originally randomized and treated with zofenopril and in 43.8% of patients treated with ramipril [odds ratio (OR) and 95% confidence interval, 0.65 (0.43–0.98), P = 0.041]. Such a result was achieved through a significantly larger reduction in CV hospitalization under zofenopril [OR: 0.61 (0.37–0.99), P = 0.047], whereas reduction in mortality rate with zofenopril did not achieve statistical significance versus ramipril [OR: 0.75 (0.36–1.59), P = 0.459]. These results were in line with those achieved during the initial 1-year follow-up. Benefits of early treatment of patients with LVD after acute myocardial infarction with zofenopril are sustained over many years as compared to ramipril.

show abstract

“…Several studies have been reported on the interaction between ACE inhibitors and NSAIDs [5][6][7][8][9][10][11]. Likewise, there are number of possible drug interactions of lisinopril with NSAIDs [12][13][14][15].The study of potential drug interactions of lisinopril with various NSAIDs requires the quantitation of both of these drugs in various samples containing both of these types of drugs. A number of RP-HPLC methods are reported for the determination of lisinopril in dosage forms and spiked human plasma through derivatization [16] and in human plasma with fluorescence detection [17].…”

Section: Introductionmentioning

confidence: 99%

RP-HPLC Method for the Simultaneous Determination of Lisinopril and NSAIDs in API, Pharmaceutical Formulations and Human Serum

Sultana¹,

Arayne²,

Siddiqui³

et al. 2012

AJAC

View full text Add to dashboard Cite

High performance liquid chromatographic method was developed valdated and applied for the simultaneous determi- nation of lisinopril and NSAIDs in bulk, pharmaceuticals formulations and human serum. A Purospher star C18 (5 µm, 25 × 0.46 cm) column was used with mobile phase consisting of methanol: water: acetonitrile (80:17.5:2.5 v/v, pH 3.0) and quantitative evaluation was performed at 225 nm with a flow rate of 1.0 mL?min–1. The retention time of lisinopril was 2.2 min while naproxen, flurbiprofen, diclofenac sodium and mefenamic acid were found to be 4.0, 4.5, 5.0 and 6.7 min respectively. Suitability of this method for the quantitative determination of the drugs was proved by validation in accordance with the requirements laid down by International Conference on Harmonization (ICH) guidelines. The method is selective, precise, accurate and can be used for analysis of pharmaceutical preparations in quality control and clinical laboratories

show abstract

Adverse Interactions of Rofecoxib with Lisinopril in Spontaneously Hypertensive Rats

Abstract: These results indicate that COX-2 inhibitors should be used judiciously in patients with history of hypertension, ischemic heart disease, or chronic renal failure.

Cited by 5 publications

References 55 publications

New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study

RP-HPLC Method for the Simultaneous Determination of Lisinopril and NSAIDs in API, Pharmaceutical Formulations and Human Serum

Contact Info

Product

Resources

About